ABSITE - TRANSFUSION-COAGULATION – QUESTIONS WITH CORRECT ANSWERS 2025

ABSITE - TRANSFUSION/COAGULATION
– QUESTIONS WITH CORRECT
ANSWERS 2025
AntithrombinNIIINdeficiencyNisNaNcommonlyNobservedNhypercoagulableNstate.NWhichNofNtheNfollowingNstat
ementsNisNtrueNconcerningNthisNcondition?



A.NThromboticNepisodesNareNrelatedNtoNpredisposingNeventsNsuchNasNoperations,Nchildbirth,NandNinfection
N



B.NAllNofNtheNabove
N



C.NANpatientNwithNthisNdeficiencyNusuallyNhasNthrombosisNwhileNtakingNheparinNorNhasNanNinabilityNtoNachi
eveNadequateNanticoagulationNwithNheparin
N



D.NAntithrombinNIIINdeficiencyNcanNbeNeitherNcongenitalNorNacquiredN-NCORRECTNANSWERN-
AllNofNtheNabove

Correct.

AntithrombinNIIINdeficiencyNaccountsNforNapproximatelyN2%NofNvenousNthromboticNevents.NThisNdeficienc
yNhasNbeenNdescribedNamongNpatientsNwithNpulmonaryNembolism,NmesentericNvenousNthrombosis,Nlower
NextremityNvenousNthrombosis,NarterialNthrombosis,NandNdialysisNfistulaNfailure.NAntithrombinNIIINisNaNseri

neNproteaseNinhibitorNofNthrombinNandNfactorsNXa,NIXa,NandNXIa.NBecauseNoneNofNtheNmainNactionsNofNhep
arinNisNtoNpotentiateNtheNanticoagulantNeffectsNofNantithrombinNIII,NaNpatientNwithNthisNdeficiencyNusuallyN
hasNthrombosisNwhileNtakingNheparinNorNhasNanNinabilityNtoNachieveNadequateNanticoagulationNwithNhepa
rin.NAntithrombinNIIINdeficiencyNcanNbeNeitherNcongenitalN(1NinN2,000NtoN5,000Nbirths)NorNacquired.NAcquir
edNdefectsNoccurNwithNinadequateNproduction,NasNinNliverNdisease,NmalignantNdisease,NnephroticNsyndro
me,NdisseminatedNintravascularNcoagulation,Nmalnutrition,NorNincreasedNproteinNcatabolism.NThromboticN
episodesNareNrelatedNtoNpredisposingNeventsNsuchNasNoperations,Nchildbirth,NandNinfections.NOnceNtheNdia
gnosisNofNantithrombinNIIINdeficiencyNisNestablished,NfreshNfrozenNplasmaNisNadministeredNandNisNfollowed
NbyNlong-termNtreatmentNwithNwarfarin.




WhichNofNtheNfollowingNstatementsNisNtrueNconcerningNheparin-associatedNthrombocytopenia?



A.NHeparin-associatedNthrombocytopeniaNoccursNonlyNwithNexcessiveNanticoagulationNwithNheparin
N


B.NHeparin-associatedNthrombocytopeniaNcanNoccurNwithinNhoursNofNinitiationNofNheparinNtherapy

,N



C.NHeparin-
associatedNthrombocytopeniaNisNcausedNbyNaggregationNofNplateletsNandNcanNresultNinNthrombosisNorNem
bolicNepisodes
N



D.NSevereNthrombocytopeniaN(plateletNcountN<100,000/µL)NoccursNamongN40%NofNpatientsNtreatedNwithN
heparinN-NCORRECTNANSWERN-Heparin-
associatedNthrombocytopeniaNisNcausedNbyNaggregationNofNplateletsNandNcanNresultNinNthrombosisNorNem
bolicNepisodes

Correct.

Heparin-
associatedNthrombocytopeniaNoccursNamongN0.6%NtoN30%NofNpatientsNwhoNreceiveNheparin,NalthoughNse
vereNthrombocytopeniaN(plateletNcountsNlessNthanN100,000/µL)NoccursNamongNfewerNthanN10%NofNpatien
tsNtreatedNwithNheparin.NHeparin-
associatedNthrombocytopeniaNisNcausedNbyNaNplasmaNfactor,NmostNlikelyNaNheparin-
dependentNplateletNantibody,NthatNcausesNaggregationNofNplateletsNwhenNexposedNtoNheparin.NActivation
NofNplateletsNinNthisNsettingNresultsNinNthrombocytopenia,Nthrombosis,NandNembolicNepisodes,NwhichNcanNl

eadNtoNdeath.NBothNbovineNandNporcineNheparinNhaveNbeenNassociatedNwithNthisNsyndrome,NwhichNusuall
yNbeginsN5NtoN15NdaysNafterNinitiationNofNheparinNtherapy.NEvenNtrivialNexposureNtoNheparin,NsuchNasNtheNc
oatingNonNpulmonaryNarterialNcathetersNorNlow-
rateNinfusionNintoNarterialNcatheters,NcanNcauseNthisNsyndrome.



WhichNofNtheNfollowingNstatementsNisNtrueNconcerningNhemophiliaNA?



A.LaboratoryNtestsNrevealNaNprolongationNofNactivatedNpartialNthromboplastinNtimeN(aPTT),NprothrombinNt
ime,NthrombinNclottingNtime,NandNplateletNaggregation
N


B.NSpontaneousNbleedingNisNunusualNwithNfactorNVIIINlevelsNgreaterNthanN50%NofNnormal
N


C.NHemophiliaNANisNinheritedNasNaNsex-linkedNrecessiveNdeficiencyNofNfactorNVIII
N



D.NAllNpatientsNhaveNaNfamilyNhistoryNofNbleedingNdisordersN-NCORRECTNANSWERN-
HemophiliaNANisNinheritedNasNaNsex-linkedNrecessiveNdeficiencyNofNfactorNVIII

Correct.

HemophiliaNANisNinheritedNasNaNsex-
linkedNrecessiveNdeficiencyNofNfactorNVIII,NalthoughNnoNcasesNareNcausedNbyNspontaneousNmutation.NTheNi
ncidenceNofNthisNabnormalityNisNapproximatelyN1NinN10,000Nbirths.NLaboratoryNscreeningNtestsNusuallyNrev
ealNprolongationNofNtheNaPTTNbutNaNnormalNprothrombinNtime,NthrombinNclottingNtime,NandNplateletNaggr

, egation.NTheNminimumNlevelNofNVIIINrequiredNforNhemostasisNisN30%NforNminorNbleeding;NspontaneousNble
edingNisNunusualNwithNfactorNlevelsNgreaterNthanN5%NtoN10%NofNnormal.NInNsevereNgeneticNdeficiencyNstat
es,Nhowever,NfactorNlevelsNasNlowNasN1%NhaveNbeenNfound,NandNpatientsNareNatNriskNofNspontaneousNbleed
ing.



EachNofNtheNfollowingNmayNcontributeNtoNrecalcitrantNcoagulopathyNinNaNpatientNsufferingNfromNmassiveNt
raumaNEXCEPT:



A.NmassiveNtransfusion
N



B.NmetabolicNalkalosis
N



C.NactiveNmajorNhemorrhage
N



D.NcoreNhypothermia
N



E.NthrombocytopeniaN-NCORRECTNANSWERN-metabolicNalkalosis

Correct.

InNtheNpresenceNofNongoingNactiveNhemorrhage,NtraumaNvictimsNareNproneNtoNdevelopNaNrecalcitrantNcoa
gulopathy.NTheNmassiveNtransfusionNrequirementNinNsuchNpatientsNisNassociatedNwithNcoreNhypothermiaNa
ndNthrombocytopenia,NbothNofNwhichNcontributeNtoNtheNcoagulopathy.NMetabolicNacidosis,NnotNalkalosis,N
isNcharacteristicNofNthisNsyndrome,NandNtheNacidosisNisNanotherNcontributingNfactorNtoNtheNbleedingNprobl
em.NAlthoughNongoingNactiveNhemorrhageNcanNcontributeNtoNthrombocytopeniaNandNtheNneedNforNblood
Ntransfusion,NitNisNnotNaNdirectNcontributorNtoNtheNcoagulopathy.




AN67-year-oldNmanNwithNadvancedNcholangiocarcinomaNhasNgram-
negativeNsepsis.NExcessiveNbleedingNisNdetectedNaroundNvascularNcathetersNandNfromNneedleNpunctureNsit
es.NTheNdiagnosisNofNdisseminatedNintravascularNcoagulationNisNconsidered.NWhichNofNtheNfollowingNlabor
atoryNtestsNisNindicativeNofNdisseminatedNintravascularNcoagulation?



A.NNormalNprothrombinNtime
N



B.NIncreasedNplateletNcount
N


C.NDecreasedNfibrinNsplitNproducts